Published

New frontiers in the biosynthesis of psychoactive specialized metabolites.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Current opinion in plant biology
Date: 2024-12-01
Source: PubMed
DOI: 10.1016/j.pbi.2024.102626
PubMed: 39288539

Authors

Li G Facchini PJ

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Mechanism of Action Clinical Trial Review Article Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Genome-based optimization of psilocybin and N,N-dimethyltryptamine biosynthetic pathways in E. coli using CRISPR-associated transposases2026-09-01 New frontiers in the biosynthesis of psychoactive specialized metabolites.2024-12-01

Related papers

Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-16 Assessing Canadian Policy Readiness for Psychedelic-Assisted Therapy in Cancer CareUnknown journal · 2026-08-17 Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians.Drugs · 2026-08-01 Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.Hearing research · 2026-08-01 A suite of engineered mice for interrogating psychedelic drug actions.Nature neuroscience · 2026-08-06 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trialCommunications Medicine · 2026-07-30